Aduro Biotech Inc (ADRO.OQ)
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|68||2008||Chairman of the Board, President and Chief Executive Officer|
|52||2013||Chief Operating Officer|
|51||2015||Executive Vice President, General Counsel, Secretary|
|48||2016||Executive Vice President of Research and Development|
|44||2015||Senior Vice President - Finance|
- BRIEF-Aduro Biotech announces data from preclinical studies with ADU-1604
- BRIEF-Aduro Biotech reports Q3 loss per share $0.33
- BRIEF-Aduro Biotech announces first patient dosed in Phase 1 clinical trial of personalized immunotherapy pLADD
- BRIEF-Aduro Biotech announces advancement of adu-s100 into global combination trial with pdr001 for the treatment of solid tumors and lymphomas
- BRIEF-HitGen and Aduro Enter Research Collaboration